Unaudited Financial Results for the quarter ended on June 30, 2026.
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 05 Aug 2026, 05:49 PM IST · BSE ID: 5a1570a3-97bb-41c3-965c-c2b5e7c2ed8c
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its first quarter financial results, with standalone profit but a consolidated loss, and scheduled its annual meeting.
🤖 AI Summary
- Board approved unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.
- Standalone Net Profit for Q1 FY27 stood at Rs. 365.71 Lakhs.
- Consolidated Net Loss for Q1 FY27 was Rs. (356.33) Lakhs.
- The 33rd Annual General Meeting is set for Saturday, September 19, 2026, via Video Conferencing.
- Re-appointment of Mr. Hemang Shah as Executive Director for five years was approved, awaiting member sanction.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations (Q1 FY27)
5,550.10 Rs. In Lakhs
-41.19
Standalone Net Profit (Q1 FY27)
365.71 Rs. In Lakhs
-63.43
Consolidated Revenue from operations (Q1 FY27)
9,373.65 Rs. In Lakhs
-19.20
Consolidated Net Profit / (Loss) (Q1 FY27)
(356.33) Rs. In Lakhs
308.41
Standalone Basic EPS (Q1 FY27)
5.31 Rs.
-63.47
Standalone Total expenses (Q1 FY27)
5,162.35 Rs. In Lakhs
-37.50
🏢 How This Affects the Company
Standalone Net Profit for Q1 FY27 was Rs. 365.71 Lakhs, a decrease from Rs. 999.95 Lakhs in the prior comparable period. Consolidated Net Loss was Rs. (356.33) Lakhs, an increase from Rs. (87.25) Lakhs in the prior comparable period.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are required to review the notice for the 33rd Annual General Meeting scheduled for September 19, 2026, and participate in the e-voting process for resolutions including director re-appointment.
👤
Who Is Affected
All shareholders are affected by the financial performance, particularly by the decline in standalone net profit and widening consolidated net loss. Shareholders will also vote on the re-appointment of Mr. Hemang Shah as Executive Director.
🔍
Management Signal
The decision to approve Mr. Hemang Shah's re-appointment for five years signals management's intent for continuity in executive leadership, subject to member approval.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Annual General Meeting on September 19, 2026 — confirmation of director re-appointment.
Q2 FY27 Financial Results — review trend in standalone profit and consolidated loss.
Management Discussion and Analysis Report — details on factors impacting current quarter performance.
MEDIUM RISK
Significant decline in standalone profit and substantial increase in consolidated net loss for the quarter.
💡 Investor Takeaway
Bharat Parenterals reported Q1 FY27 standalone Net Profit of Rs. 365.71 Lakhs, a 63.43% decrease from Rs. 999.95 Lakhs in Q1 FY26. Consolidated Net Loss widened to Rs. (356.33) Lakhs from Rs. (87.25) Lakhs in the prior comparable period.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Net Profit for Q1 FY27 was Rs. 365.71 Lakhs, indicating continued profitability on a standalone basis.
- Standalone EBITDA (excluding other income) to Revenue from operation ratio improved to 12.30% in Q1 FY27 from 0.06% in Q4 FY26.
⚠️ Concerns
- Standalone Net Profit decreased by 63.43% to Rs. 365.71 Lakhs in Q1 FY27 from Rs. 999.95 Lakhs in Q1 FY26.
- Consolidated Net Loss widened significantly to Rs. (356.33) Lakhs in Q1 FY27 from a loss of Rs. (87.25) Lakhs in Q1 FY26.
❓ Frequently Asked Questions
What was Bharat Parenterals' standalone net profit for the quarter ended June 30, 2026?
Bharat Parenterals reported a standalone Net Profit of Rs. 365.71 Lakhs for the quarter ended June 30, 2026.
What was Bharat Parenterals' consolidated net profit or loss for Q1 FY27?
Bharat Parenterals reported a consolidated Net Loss of Rs. (356.33) Lakhs for the quarter ended June 30, 2026.
When is Bharat Parenterals' 33rd Annual General Meeting scheduled?
The 33rd Annual General Meeting of Bharat Parenterals Limited is scheduled for Saturday, September 19, 2026.
Who was approved for re-appointment as an Executive Director by Bharat Parenterals' board?
Mr. Hemang Shah (DIN: 03024324) was approved for re-appointment as an Executive Director for five consecutive years, subject to member approval.
Questions based on this BSE filing only. For information purposes.